Issues
Deals
Research
Ledger
About
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
European Commission funds NUDZ
·
$0.22m
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
Pfizer buys Metsera
·
no dollar price
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
no dollar price
AbbVie takes an option on Gilgamesh
·
$2bn
Next issue
Issue 23 · Tue 17 Nov
All issues
Research
Published evidence, methods and the quality of the science itself.
5 issues
2026-06-30
No. 4
LSD just posted the biggest depression number in psychedelic Phase 3 history.
TRIALS
RESEARCH
DEFINIUM
COMPASS
2026-06-23
No. 3
Europe's most advanced psychedelic Phase 3 is staked on the one indication that got harder last week.
TRIALS
RESEARCH
COMPASS
CYBIN
2026-06-16
No. 2
Blind the psilocybin trials in TRD, and the effect shrinks
RESEARCH
TRIALS
ATAIBECKLEY
2026-06-11
European Psychedelic Medicine: H1 2026 in Review
RESEARCH
DEALS
COMPASS
ATAIBECKLEY
BECKLEY-PSYTECH
GH
2026-06-09
No. 1
Psychedelic Brief
RESEARCH
ACCESS
GH
COMPASS